| 000 | 01737 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250517114228.0 | ||
| 264 | 0 | _c20170512 | |
| 008 | 201705s 0 0 eng d | ||
| 022 | _a1095-6859 | ||
| 024 | 7 |
_a10.1016/j.ygyno.2016.08.328 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAlHilli, Mariam M | |
| 245 | 0 | 0 |
_aIn vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma. _h[electronic resource] |
| 260 |
_bGynecologic oncology _cNov 2016 |
||
| 300 |
_a379-388 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aDNA-Binding Proteins _xanalysis |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGenes, BRCA2 |
| 650 | 0 | 4 | _aHomologous Recombination |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIndazoles _xtherapeutic use |
| 650 | 0 | 4 |
_aOvarian Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aPiperidines _xtherapeutic use |
| 650 | 0 | 4 |
_aPoly(ADP-ribose) Polymerase Inhibitors _xtherapeutic use |
| 650 | 0 | 4 | _aPromoter Regions, Genetic |
| 700 | 1 | _aBecker, Marc A | |
| 700 | 1 | _aWeroha, S John | |
| 700 | 1 | _aFlatten, Karen S | |
| 700 | 1 | _aHurley, Rachel M | |
| 700 | 1 | _aHarrell, Maria I | |
| 700 | 1 | _aOberg, Ann L | |
| 700 | 1 | _aMaurer, Matt J | |
| 700 | 1 | _aHawthorne, Kieran M | |
| 700 | 1 | _aHou, Xiaonan | |
| 700 | 1 | _aHarrington, Sean C | |
| 700 | 1 | _aMcKinstry, Sarah | |
| 700 | 1 | _aMeng, X Wei | |
| 700 | 1 | _aWilcoxen, Keith M | |
| 700 | 1 | _aKalli, Kimberly R | |
| 700 | 1 | _aSwisher, Elizabeth M | |
| 700 | 1 | _aKaufmann, Scott H | |
| 700 | 1 | _aHaluska, Paul | |
| 773 | 0 |
_tGynecologic oncology _gvol. 143 _gno. 2 _gp. 379-388 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.ygyno.2016.08.328 _zAvailable from publisher's website |
| 999 |
_c26406988 _d26406988 |
||